Pulmonary Hypertension: Risk stratification. Impact of its reduction in the prognosis

Abstract

Pulmonary hypertension is an incurable disease with a median survival of 7 years, which in the chronic stage is characterized by high morbidity and mortality with multiple hospitalizations that announce a rapid progression of the disease. Therefore, the ability of the doctor to diagnose, assess the etiology, determine the progression, and determine the exact risk is essential in order to determine the optimal care of patients, and its appropriate therapy. The prediction of a comprehensive risk is essential to individualize therapeutic decisions, for which several tools are available to assess risk, including those of the European Society of Cardiology / European Respiratory Society (2015), the Nice Guidelines for Pulmonary Hypertension (2013-2018), or the equation of the French registry, among others. None of the risk prediction scores have been prospectively validated; however, the guidelines have been able to extract data from them to develop a warning system that helps to stratify the risk and provide a prognostic algorithm.